Key statistics dashboard for Krystal Biotech, Inc. (KRYS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa.
Stock Data
| Price | $337.85 |
| Market Cap | $10.0B |
| Enterprise Value | $9.63B |
| Beta | 0.54 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | 40.78 |
| Price / Book | 7.33 |
| P/S | 22.57 |
| EV/EBITDA | 44.09 |
| EV/Sales | 21.86 |
| EV/FCF | 37.36 |
| P/FCF | 38.57 |
| Earnings Yield | 2.40% |
| FCF Yield | 2.57% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 93.34% |
| EBIT Margin | 48.43% |
| EBITDA Margin | 49.59% |
| Operating Margin | 44.93% |
| Net Margin | 54.82% |
| Return on Equity | 19.34% |
| Return on Assets | 16.09% |
| Return on Invested Capital | 14.39% |
| Return on Capital Employed | 14.41% |
Financial Health
| Current Ratio | 8.32 |
| Quick Ratio | 7.96 |
| Cash Ratio | 3.36 |
| Debt / Equity | 0.01 |
| Debt / Assets | 0.59% |
| Net Debt / EBITDA | -1.92 |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 14.92 |
| Book Value per share | 46.03 |
| Cash per share | 28.64 |
| FCF per share | 8.73 |
| Tangible Book Value per share | 46.03 |
| Dividend per share | 0.00 |
Related companies: ACLX · ALKS · ARWR · CRSP · MTSR · PCVX · PTCT
Explore sector: Healthcare · Biotechnology
More sections of KRYS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks